Persistent production of an integrase-deleted HIV-1 variant with no resistance mutation and wild-type proviral DNA in a treated patient by MA Trabaud et al.
ORAL PRESENTATION Open Access
Persistent production of an integrase-deleted
HIV-1 variant with no resistance mutation and
wild-type proviral DNA in a treated patient
MA Trabaud*, L Cotte, J Saison, C Ramiere, C Ronfort, JC Tardy, P Andre
From International Symposium HIV and Emerging Infectious Diseases 2014
Marseille, France. 21-23 May 2014
Introduction
An HIV-1-infected patient with suppressed viremia for
several years, in whom a variant carrying a deleted inte-
grase (IN) gene, without reverse transcriptase (RT) or
protease (PR) resistance mutations, emerged in the
plasma and persisted is described.
Materials and methods
Viral load (VL) was tested by routine assays following
manufacturer’s instructions. RT, PR and IN genes were
sequenced with the ANRS consensus techniques.
Nested PCRs with patient virus IN-specific primers and
probes were developed to detect the deleted variant from
plasma, blood lymphocytes, rectal biopsies, and sperm.
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Results
VL remained undetectable for more than two years
under therapy, excepted for 1 observed blip. Thereafter
HIV RNA increased slightly but persistently, fluctuating
from 56 to 466 copies/ml during more than five years.
By population sequencing a 38 nucleotides deletion was
observed in the IN C-terminal domain (CTD) encoding
sequence (residues 215 to 227 of the WT IN).
In plasma, the variant progressively emerged during
therapy-induced virosuppression, HIV RNA being unde-
tectable by routine viral load assay, and then persisted
during detectable viremia. The WT IN, not detected by
bulk sequencing, was present but at stable low level.
HIV DNA and RNA with WT IN were amplified from
each cell extract. Detection of the deleted IN was a very
rare event in blood and rectal cells.
Conclusions
Although the reservoir of this virus is yet unknown it is
likely in a tissue compartment and not predominantly in
cells migrating through blood.
Questions arising from this case are how and why this
certainly defective variant emerged during efficient viro-
suppression, and how it could be preferentially and sta-
bly produced.
As for interpretation of residual viremia found in
long-term treated patients with undetectable viral load,
virus production can originate from on-going replica-
tion, but the cells had to be continuously co-infected
with the two viral forms, or synthesis by chronically
infected cells. However, the defective virus production
at detectable level suggests unusual circumstances.
Anyway, this case raises concern about the possible
long term synthesis of defective viruses.
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